F2R and coronary artery disorder: In line with these findings, the selective inhibition of PAR-1 with vorapaxar resulted in a significant decrease in thrombotic events in patients with coronary artery disease on DAPT but also led to an increase in bleeding complications, including cerebral hemorrhage [34].